J&J Partners With Sail Biomedicines on In Vivo CAR-T for Autoimmune Disease, Holds Option to Acquire

Johnson & Johnson announced strategic agreements and a collaboration with Sail Biomedicines, a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases.¹ J&J will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives built in to expand the platform's application across additional therapeutic targets over time.¹ J&J will also make an equity investment in Sail and has been granted an exclusive option to acquire the company for $2.58 billion.¹

Under the terms of the agreements, J&J will make total initial payments of $785 million, including a $465 million equity investment, plus additional contingent payments of $140 million tied to development milestones.¹ Should J&J exercise its acquisition option, the company expects the agreements to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.18 in 2026 and approximately $1.28 in 2027.¹ The transactions remain subject to applicable regulatory approvals and other customary conditions.¹

John Reed, executive vice president, Innovative Medicine Research & Development, Johnson & Johnson, said, "People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control. Sail's innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way. By working together with Sail, we aim to accelerate the development of innovative therapies that have the potential to fundamentally transform how immune-mediated diseases are treated."¹

How does in vivo CAR-T differ from conventional CAR-T therapy?

Unlike traditional cell therapies, which require extracting a patient's T cells, genetically engineering them outside the body, and reinfusing them after lymphodepletion, Sail's platform is designed to reprogram a patient's immune cells directly within the body, with the stated goal of resetting the immune system to deliver durable disease control.¹ This in vivo approach is part of a broader wave of platforms attempting to eliminate the manufacturing complexity, cost, and treatment-center burden associated with conventional autologous and allogeneic CAR-T therapies, an approach also being pursued by companies including CREATE Medicines, which uses mRNA-lipid nanoparticle technology to engineer immune cells directly inside the body for both autoimmune disease and oncology indications.²

Why is J&J pursuing autoimmune disease specifically through this platform?

CAR-T therapies have historically been developed and approved for hematologic malignancies, where they work primarily by depleting B cells, the same cell population implicated in driving autoantibody production in autoimmune diseases such as lupus.⁴ That mechanistic overlap has driven growing industry interest in applying CAR-T-based B-cell depletion to autoimmune disease, with in vivo delivery approaches like Sail's emerging as one of several competing strategies alongside ex vivo autologous and allogeneic formats.⁴ Imviva Biotech, for example, has reported early remission data for its own allogeneic CD19/BCMA-targeted CAR-T candidate in lupus, with translational data suggesting deep B-cell depletion followed by reconstitution of non-autoimmune B-cell populations.³ That program uses a different delivery approach than Sail's in vivo platform, but reflects the same broader industry interest in B-cell-directed CAR-T for autoimmune disease.

How does this fit into J&J's broader immunology strategy?

J&J said the Sail collaboration builds on its existing leadership in immunology and established CAR-T expertise in oncology, expanding the company's capabilities in in vivo CAR-T specifically and strengthening its position in immune system reprogramming.¹ The deal structure, an initial collaboration and equity stake paired with an exclusive acquisition option rather than an outright purchase, gives J&J a way to secure early access to Sail's platform and lead program while deferring the larger capital commitment until specific development milestones are reached.

What happens next?

The transactions are subject to regulatory approval and other customary closing conditions.¹ Should J&J exercise its option to acquire Sail, the company has indicated this would follow further development progress and additional contingent milestone payments.¹

References

1. Johnson & Johnson. Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance In Vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset. Press Release, July 29, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-sail-biomedicines-to-advance-in-vivo-car-t-programs-and-transform-autoimmune-disease-through-immune-reset
2. Marisol F. CREATE Medicines Secures $122 Million to Advance In Vivo CAR-T Pipeline. BioPharm International. May 14, 2026. https://www.biopharminternational.com/view/create-medicines-secures-122-million-advance-in-vivo-car-t-pipeline
3. Schoenthaler E. Imviva Highlights Early Remission Data for Allogeneic CAR-T Therapy in Lupus at ASGCT 2026. BioPharm International. May 15, 2026. https://www.biopharminternational.com/view/imviva-highlights-early-remission-data-for-allogeneic-car-t-therapy-in-lupus-at-asgct-2026
4. Senior, M, Grieshaber-Bouyer, R. B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers? Nat Biotechnol. April 2026. https://pubmed.ncbi.nlm.nih.gov/41807826/